The drug developer raised nearly $330m earlier this year according to its IPO filing, with $110m being supplied by SoftBank Vision Fund.

Lilly Asia Ventures returned to take part in a series B round led by Access Industries unit Access Biotechnology that took Passage Bio's funding to $226m to date.

Returning investor Kaiser Permanente Ventures contributed to a round that brought on-demand behavioural health app developer Ginger's lifetime funding to $63m.

Renee Ryan and Marianne De Backer have moved on from corporate venturing vehicle Johnson & Johnson Innovation – JJDC for roles at Cala Health and Bayer respectively.

Gyroscope Therapeutics, a dry AMD treatment developer exploiting University of Cambridge research, has secured $61.2m from cornerstone investors Cambridge Innovation Capital and Syncona.

Leveraging University of Glasgow and University of Southern Denmark research, Caldan is targeting a free fatty acid receptor associated with fatty liver disease and type 2 diabetes.

Novartis, Medtronic and SinoPharm will exit the stem cell-based diabetes therapy developer in an acquisition by Vertex Pharmaceuticals.

Novartis, Medtronic and SinoPharm will exit the stem cell-based diabetes therapy developer in an acquisition by Vertex Pharmaceuticals.

UCL and Francis Crick-founded Achilles has raised series B funding at a reported $228m valuation and will now look to advance lung cancer and melanoma treatments.

After 22 years at Eli Lilly that included laying the groundwork for its corporate venturing activities, senior vice-president of corporate business development Darren Carroll is retiring.